Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inverness Medical Innovations, a manufacturer and marketer of rapid diagnostic products, and PrognostiX, a company focused on cardiovascular disease diagnostics, have entered into a distribution agreement under which Inverness will distribute PrognostiX's CardioMPO test through its global sales and distribution infrastructure.
Subscribe to our email newsletter
Under the terms of the agreement, Inverness will have co-exclusive worldwide distribution rights with PrognostiX in all countries except Italy and Russia. PrognostiX previously secured distributors in these two countries. Financial terms of the agreement were not disclosed.
The CardioMPO test, said to be the only FDA-cleared diagnostic of its kind, measures myeloperoxidase (MPO), an enzyme found in the blood. An elevated MPO level in a patient complaining of chest pain or discomfort can signal his or her near-term risk for heart attack, bypass surgery or angioplasty, and cardiac death.
Under a separate agreement with PrognostiX and the Cleveland Clinic entered into in 2004, Inverness was granted licenses to develop MPO tests in both automated, high-throughput and low-throughput formats, including exclusive rights with respect to low-throughput detection.
Ron Zwanziger, president and CEO of Inverness Medical, said: “Inverness is enthusiastic about its collaboration with PrognostiX to commercialize its CardioMPO test. The CardioMPO Test is a great addition to our portfolio of cardiology diagnostics that are now used in more than 60 countries worldwide.”